AbbVie's Venclexta Combo Meets Endpoints In Leukemia Study
Zacks Investment Research | Mar 23, 2020 10:20PM ET
AbbVie (NYSE:ABBV) announced positive interim analysis data from a phase III study —VIALE-A —evaluating a combination regimen of its blood cancer drug, Venclexta (venetoclax) in previously-untreated acute myeloid leukemia (“AML”) patients, who are ineligible for intensive chemotherapy.
The VIALE-A study evaluated Venclexta in combination with azacitidine (Vidaza), versus placebo in combination with azacitidine. Data from the first interim analysis of the study, showed that Venclexta combo met the study’s co-primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi), compared to placebo arm.
An independent data monitoring committee recommended early report of the study data and submission to regulatory authorities based on positive efficacy results. Detailed data from the study will be presented at a future medical meeting or published in a peer-reviewed journal.
AbbVie’s shares have declined 27.2% so far this year compared with the industry’s decrease of 21%
Please note that AbbVie co-develops and co-commercializes Venclexta with Roche (OTC:RHHBY) .
Venclexta is approved in combination with chemotherapy — azacitidine, decitabine or LDAC —under accelerated pathway for the treatment of newly-diagnosed AML. AbbVie and Roche were conducting two phase III studies — VIALE-A and VIALE-C — as confirmatory studies to convert the accelerated approval into continued approval.
In February, the companies announced that VIALE-C failed to meet its primary endpoint . The study evaluated Venclexta in combination with low-dose cytarabine (“LDAC”) for improvement in OS. Although the Venclexta-LDAC combination regimen failed to show statistically significant improvement of OS, data indicated clinical activity in patients.
Venclexta is also approved as monotherapy and in combination with Roche’s Gazyva or Roche/Biogen’s (NASDAQ:BIIB) Rituxan for treating chronic lymphocytic leukemia or small lymphocytic lymphoma.
AbbVie is strengthening its oncology portfolio through label expansions of marketed drugs as well as new drug development. It believes that oncology will be its major growth driver over the next 10 years. Apart from Venclexta, another key cancer drug in AbbVie’s portfolio includes Imbruvica, which it co-develops and co-commercializes Imbruvica with J&J (NYSE:JNJ) .
Get The News You Want
AbbVie Inc. Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.